TherapeuticsMD, Inc. (TXMD) Shares Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp grew its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 13.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,877,864 shares of the company’s stock after buying an additional 2,985,846 shares during the quarter. Bank of New York Mellon Corp owned 11.96% of TherapeuticsMD worth $136,894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. lifted its holdings in shares of TherapeuticsMD by 10.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock valued at $3,659,000 after buying an additional 67,855 shares during the period. Carl Domino Inc purchased a new stake in shares of TherapeuticsMD in the 2nd quarter worth $235,000. Raymond James Financial Services Advisors Inc. increased its stake in shares of TherapeuticsMD by 293.0% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 112,900 shares of the company’s stock worth $595,000 after purchasing an additional 84,170 shares in the last quarter. Stifel Financial Corp increased its stake in shares of TherapeuticsMD by 377.9% in the 2nd quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after purchasing an additional 1,622,668 shares in the last quarter. Finally, Bamco Inc. NY increased its stake in shares of TherapeuticsMD by 126.8% in the 2nd quarter. Bamco Inc. NY now owns 850,000 shares of the company’s stock worth $4,479,000 after purchasing an additional 475,200 shares in the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.
Shares of TherapeuticsMD, Inc. (NASDAQ TXMD) opened at $5.99 on Wednesday. TherapeuticsMD, Inc. has a 12 month low of $3.50 and a 12 month high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same quarter in the prior year, the business posted ($0.13) EPS. TherapeuticsMD’s revenue for the quarter was down 19.7% compared to the same quarter last year. equities analysts anticipate that TherapeuticsMD, Inc. will post -0.37 EPS for the current fiscal year.
In other news, Director Tommy G. Thompson acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was purchased at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the completion of the transaction, the director now directly owns 3,555 shares in the company, valued at approximately $21,294.45. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 23.92% of the company’s stock.
Several equities research analysts have recently commented on TXMD shares. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 25th. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $10.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research note on Thursday, August 17th. Jefferies Group LLC restated a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research note on Friday, September 8th. Finally, Deutsche Bank AG set a $10.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $14.72.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD, Inc. (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.